Skip to main content
. Author manuscript; available in PMC: 2013 Jan 1.
Published in final edited form as: Hepatology. 2011 Nov 14;55(1):39–48. doi: 10.1002/hep.24628

Figure 2. PegIFN/RBV therapy results in preferential phosphorylation of STAT1 over STAT4 in NK cells.

Figure 2

(A–B) Maximal changes in pSTAT1 (A) and pSTAT4 (B) expression levels in chronic HCV patients of total CD3-CD56+ NK cells (left panel) and their CD56bright (middle panel) and CD56dim (right panel) subsets prior to and following PegIFN/RBV therapy initiation. (C) pSTAT1/pSTAT4 ratio (MFI) throughout the first 48h of therapy. *P<0.05, **P<0.01, **P<0.001 (comparing the indicated individual time points to the 0h time point).